Search research articles
Contact Us
Filters
Showing results (311-320 of 332) with videos related to
Page
of 34
Sort By:
Angiogenesis
|
December 2, 2022
Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy
Patrycja Nowak-Sliwinska, Judy R van Beijnum, Christian J Griffioen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen, Eleni Frangou, Bhavna Oza, et al.
Clinical Genitourinary Cancer
|
December 15, 2020
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers
Saskia Lisa Verhaart, Yasmin Abu-Ghanem, Sasja F Mulder, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting
Angela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Robert J Motzer, Axel Bex, Paul Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer
Kevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Clinical Genitourinary Cancer
|
February 17, 2016
Safety and Feasibility of Laparoscopic Nephrectomy for Big Tumors (≥ 10 cm): A Retrospective Multicentric Study
Grégory Verhoest, Jean-Philippe Couapel, Emmanuel Oger, et al.
BMC Cancer
|
July 11, 2023
The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs
Hilin Yildirim, Christiaan V Widdershoven, Maureen Jb Aarts, et al.
Contemporary Clinical Trials Communications
|
November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
Page
of 34
Search research articles
Search
Showing results (311-320 of 332) with videos related to
Sort By:
Page
of 34
Angiogenesis
|
December 2, 2022
Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy
Patrycja Nowak-Sliwinska, Judy R van Beijnum, Christian J Griffioen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen, Eleni Frangou, Bhavna Oza, et al.
Clinical Genitourinary Cancer
|
December 15, 2020
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers
Saskia Lisa Verhaart, Yasmin Abu-Ghanem, Sasja F Mulder, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting
Angela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Robert J Motzer, Axel Bex, Paul Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer
Kevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Clinical Genitourinary Cancer
|
February 17, 2016
Safety and Feasibility of Laparoscopic Nephrectomy for Big Tumors (≥ 10 cm): A Retrospective Multicentric Study
Grégory Verhoest, Jean-Philippe Couapel, Emmanuel Oger, et al.
BMC Cancer
|
July 11, 2023
The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs
Hilin Yildirim, Christiaan V Widdershoven, Maureen Jb Aarts, et al.
Contemporary Clinical Trials Communications
|
November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
Page
of 34